You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
兆科眼科(06622.HK)就馬來西亞商業化貝美素(口塞)嗎洛爾滴眼液訂立分銷協議
阿思達克 03-05 17:09
兆科眼科-B(06622.HK)宣布,已與馬來西亞綜合藥企發馬製藥,就貝美素(口塞)嗎洛爾滴眼液訂立分銷及供應協議。 該藥物由兆科眼科研發及生產的用於治療青光眼的固定劑量組合仿製藥,用於降低對β-受體阻滯劑或前列腺素類似物單藥治療效果不佳的開角型青光眼及高眼壓症患者的眼壓。公司的貝美素(口塞)嗎洛爾滴眼液已於2023年3月取得中國監管機構批准並於中國進行商業化。 根據協議條款,兆科眼科有權將產品在馬來西亞的非獨家分銷權授予發馬製藥,以代表公司在當地取得藥品註冊,並進口、推廣、分銷、營銷及銷售該產品。發馬製藥將負責在馬來西亞以自有商標註冊該產品,並根據未來銷售預測向兆科眼科做出最低採購承諾。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account